Lasa Supergenerics Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: February 25, 2025, 3:37 pm

Market Cap	108 Cr.
Current Price	21.6
High / Low	33.5/19.0
Stock P/E
Book Value	18.1
Dividend Yield	0.00 %
ROCE	6.45 %
ROE	13.2 %
Face Value	10.0
PEG Ratio	0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Lasa Supergenerics Ltd

Competitors of Lasa Supergenerics Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
HP Adhesives Ltd	473 Cr.	51.5	123/47.3	24.5	19.2	0.58 %	17.7 %	12.6 %	2.00
Haryana Leather Chemicals Ltd	38.8 Cr.	79.0	124/56.8	9.42	87.2	1.27 %	8.96 %	7.25 %	10.0
Hardcastle & Waud Mfg Co Ltd	49.3 Cr.	725	1,355/563	28.2	663	0.00 %	7.00 %	5.98 %	10.0
Grauer & Weil (India) Ltd	3,817 Cr.	84.2	120/72.2	23.8	19.2	0.59 %	26.1 %	19.6 %	1.00
DMCC Speciality Chemicals Ltd	778 Cr.	312	453/245	37.3	85.4	0.32 %	7.55 %	2.89 %	10.0
Industry Average	11,415.96 Cr	725.09		46.86	173.82	0.38%	13.99%	10.73%	6.44

All Competitor Stocks of Lasa Supergenerics Ltd

Quarterly Result

Metric	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
Sales	53.99	39.10	36.07	34.11	15.74	51.21	28.88	33.66	31.70	35.32	30.56	24.30	26.66
Expenses	41.24	30.01	31.44	32.86	16.92	40.46	37.01	33.99	34.16	30.98	26.51	23.25	25.60
Operating Profit	12.75	9.09	4.63	1.25	-1.18	10.75	-8.13	-0.33	-2.46	4.34	4.05	1.05	1.06
OPM %	23.62%	23.25%	12.84%	3.66%	-7.50%	20.99%	-28.15%	-0.98%	-7.76%	12.29%	13.25%	4.32%	3.98%
Other Income	0.02	-0.00	0.01	-11.88	0.01	4.24	0.01	-2.47	0.86	-18.97	-0.00	0.08	-0.00
Interest	0.08	0.03	0.03	-0.00	0.01	0.01	0.01	0.84	0.43	0.41	0.37	0.56	0.44
Depreciation	4.09	3.94	3.47	3.45	3.59	3.61	3.07	3.09	3.09	4.17	2.65	2.68	2.68
Profit before tax	8.60	5.12	1.14	-14.08	-4.77	11.37	-11.20	-6.73	-5.12	-19.21	1.03	-2.11	-2.06
Tax %	23.84%	25.78%	29.82%	2.41%	1.05%	-6.68%	-7.95%	2.08%	3.91%	21.92%	580.58%	99.05%	29.61%
Net Profit	6.56	3.80	0.81	-13.74	-4.71	12.13	-12.08	-6.61	-4.92	-15.00	-4.95	-0.02	-1.46
EPS in Rs	1.61	0.93	0.20	-3.38	-1.16	2.98	-2.97	-1.63	-1.21	-2.99	-0.99	-0.00	-0.29

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

Metric	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Sales	0	199	244	170	167	201	137	130	122
Expenses	0	153	202	158	137	154	120	136	115
Operating Profit	0	46	41	11	30	47	16	-6	7
OPM %		23%	17%	7%	18%	24%	12%	-5%	6%
Other Income	0	-24	3	0	0	0	-8	-18	-18
Interest	0	12	11	8	8	2	0	4	2
Depreciation	0	8	18	19	17	16	15	13	13
Profit before tax	0	2	15	-16	5	30	-6	-42	-25
Tax %		-10%	19%	25%	23%	23%	13%	9%
Net Profit	0	2	12	-12	4	23	-5	-39	-26
EPS in Rs			5.40	-5.26	0.89	5.60	-1.31	-7.71	-5.46
Dividend Payout %		0%	0%	0%	0%	4%	-24%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023
YoY Net Profit Growth (%)	500.00%	-200.00%	133.33%	475.00%	-121.74%	-680.00%
Change in YoY Net Profit Growth (%)	0.00%	-700.00%	333.33%	341.67%	-596.74%	-558.26%

Lasa Supergenerics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2017-2018 to 2022-2023.

Growth

Compounded Sales Growth
10 Years:	%
5 Years:	-9%
3 Years:	-20%
TTM:	8%

Compounded Profit Growth
10 Years:	%
5 Years:	-4%
3 Years:	%
TTM:	-869%

Stock Price CAGR
10 Years:	%
5 Years:	-14%
3 Years:	-22%
1 Year:	-31%

Return on Equity
10 Years:	%
5 Years:	-1%
3 Years:	-8%
Last Year:	-13%

Last Updated: Unknown

Balance Sheet

Last Updated: December 14, 2024, 3:15 pm

Month	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	0.05	0.05	23	23	41	41	50	50	50	50
Reserves	0	75	94	82	101	118	108	68	47	41
Borrowings	0	116	107	85	48	19	20	22	22	20
Other Liabilities	0	37	63	69	42	29	31	24	32	36
Total Liabilities	0	228	287	258	232	208	209	164	151	147
Fixed Assets	0	119	170	162	152	143	137	119	110	105
CWIP	0	30	7	7	0	0	5	5	3	3
Investments	0	0	0	0	0	0	0	0	0	0
Other Assets	0	80	110	90	80	65	67	40	39	40
Total Assets	0	228	287	258	232	208	209	164	151	147

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	0	-3	40	41	14	41	9	-17	2
Cash from Investing Activity +	0	0	-44	-7	-2	-4	-3	11	-0
Cash from Financing Activity +	0	0	4	-33	-10	-36	-0	-4	-2
Net Cash Flow	0	-3	0	-0	2	1	6	-10	-0

Free Cash Flow

Month	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Free Cash Flow	0.00	-70.00	-66.00	-74.00	-18.00	28.00	-4.00	-28.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	64	63	62	45	27	50	7	13
Inventory Days	93	90	90	101	56	46	48	92
Days Payable	71	102	170	130	41	68	32	68
Cash Conversion Cycle	87	51	-18	16	42	28	22	37
Working Capital Days	58	44	-2	31	35	12	-17	34
ROCE %	42%	13%	-4%	7%	17%	1%	-12%	-6%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters	45.01%	43.78%	43.78%	43.78%	43.78%	53.65%	53.65%	53.65%	53.65%	53.65%	53.65%	53.65%
FIIs	0.06%	0.00%	0.40%	0.00%	0.00%	0.00%	0.00%	0.00%	0.01%	0.12%	0.00%	0.01%
Public	54.93%	56.21%	55.82%	56.21%	56.21%	46.34%	46.34%	46.34%	46.33%	46.23%	46.34%	46.32%
No. of Shareholders	24,827	27,859	30,087	29,692	28,936	28,818	28,031	27,770	27,161	27,615	27,217	27,968

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	-4.34	-7.71	-1.30	5.60	1.26
Diluted EPS (Rs.)	-4.34	-7.71	-1.30	5.60	1.26
Cash EPS (Rs.)	-2.21	-5.03	2.12	9.49	5.16
Book Value[Excl.RevalReserv]/Share (Rs.)	19.30	23.61	36.54	39.07	34.78
Book Value[Incl.RevalReserv]/Share (Rs.)	19.30	23.61	36.54	39.07	34.78
Dividend / Share (Rs.)	0.00	0.00	0.25	0.25	0.00
Revenue From Operations / Share (Rs.)	20.82	25.86	33.71	49.76	41.13
PBDIT / Share (Rs.)	0.45	-0.95	3.86	11.62	7.42
PBIT / Share (Rs.)	-1.68	-3.63	0.41	7.73	3.16
PBT / Share (Rs.)	-3.81	-8.44	-1.53	7.25	1.16
Net Profit / Share (Rs.)	-4.34	-7.71	-1.32	5.60	0.89
PBDIT Margin (%)	2.17	-3.69	11.44	23.36	18.04
PBIT Margin (%)	-8.05	-14.05	1.23	15.54	7.67
PBT Margin (%)	-18.31	-32.62	-4.52	14.57	2.83
Net Profit Margin (%)	-20.82	-29.80	-3.91	11.25	2.16
Return on Networth / Equity (%)	-22.47	-32.65	-3.61	14.33	2.56
Return on Capital Employeed (%)	-8.24	-15.03	1.08	18.79	8.22
Return On Assets (%)	-14.40	-23.57	-2.69	10.95	1.56
Long Term Debt / Equity (X)	0.00	0.00	0.00	0.00	0.09
Total Debt / Equity (X)	0.00	0.00	0.00	0.00	0.24
Asset Turnover Ratio (%)	0.66	0.71	0.67	0.92	0.68
Current Ratio (X)	0.77	0.91	1.65	1.59	0.99
Quick Ratio (X)	0.38	0.59	1.39	1.16	0.65
Inventory Turnover Ratio (X)	4.81	8.67	6.13	4.69	2.99
Interest Coverage Ratio (X)	1.17	-1.15	389.33	24.08	3.72
Interest Coverage Ratio (Post Tax) (X)	-5.71	-3.50	62.86	12.60	1.45
Enterprise Value (Cr.)	108.58	90.15	152.41	239.23	143.93
EV / Net Operating Revenue (X)	1.04	0.69	1.11	1.18	0.86
EV / EBITDA (X)	47.93	-18.82	9.71	5.06	4.77
MarketCap / Net Operating Revenue (X)	1.05	0.71	1.24	1.20	0.69
Price / BV (X)	1.14	0.78	1.14	1.53	0.81
Price / Net Operating Revenue (X)	1.05	0.71	1.24	1.20	0.69
EarningsYield	-0.19	-0.41	-0.03	0.09	0.03

After reviewing the key financial ratios for Lasa Supergenerics Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 24, the value is -4.34. This value is below the healthy minimum of 5. It has increased from -7.71 (Mar 23) to -4.34, marking an increase of 3.37.
For Diluted EPS (Rs.), as of Mar 24, the value is -4.34. This value is below the healthy minimum of 5. It has increased from -7.71 (Mar 23) to -4.34, marking an increase of 3.37.
For Cash EPS (Rs.), as of Mar 24, the value is -2.21. This value is below the healthy minimum of 3. It has increased from -5.03 (Mar 23) to -2.21, marking an increase of 2.82.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 19.30. It has decreased from 23.61 (Mar 23) to 19.30, marking a decrease of 4.31.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 19.30. It has decreased from 23.61 (Mar 23) to 19.30, marking a decrease of 4.31.
For Dividend / Share (Rs.), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 23) which recorded 0.00.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 20.82. It has decreased from 25.86 (Mar 23) to 20.82, marking a decrease of 5.04.
For PBDIT / Share (Rs.), as of Mar 24, the value is 0.45. This value is below the healthy minimum of 2. It has increased from -0.95 (Mar 23) to 0.45, marking an increase of 1.40.
For PBIT / Share (Rs.), as of Mar 24, the value is -1.68. This value is below the healthy minimum of 0. It has increased from -3.63 (Mar 23) to -1.68, marking an increase of 1.95.
For PBT / Share (Rs.), as of Mar 24, the value is -3.81. This value is below the healthy minimum of 0. It has increased from -8.44 (Mar 23) to -3.81, marking an increase of 4.63.
For Net Profit / Share (Rs.), as of Mar 24, the value is -4.34. This value is below the healthy minimum of 2. It has increased from -7.71 (Mar 23) to -4.34, marking an increase of 3.37.
For PBDIT Margin (%), as of Mar 24, the value is 2.17. This value is below the healthy minimum of 10. It has increased from -3.69 (Mar 23) to 2.17, marking an increase of 5.86.
For PBIT Margin (%), as of Mar 24, the value is -8.05. This value is below the healthy minimum of 10. It has increased from -14.05 (Mar 23) to -8.05, marking an increase of 6.00.
For PBT Margin (%), as of Mar 24, the value is -18.31. This value is below the healthy minimum of 10. It has increased from -32.62 (Mar 23) to -18.31, marking an increase of 14.31.
For Net Profit Margin (%), as of Mar 24, the value is -20.82. This value is below the healthy minimum of 5. It has increased from -29.80 (Mar 23) to -20.82, marking an increase of 8.98.
For Return on Networth / Equity (%), as of Mar 24, the value is -22.47. This value is below the healthy minimum of 15. It has increased from -32.65 (Mar 23) to -22.47, marking an increase of 10.18.
For Return on Capital Employeed (%), as of Mar 24, the value is -8.24. This value is below the healthy minimum of 10. It has increased from -15.03 (Mar 23) to -8.24, marking an increase of 6.79.
For Return On Assets (%), as of Mar 24, the value is -14.40. This value is below the healthy minimum of 5. It has increased from -23.57 (Mar 23) to -14.40, marking an increase of 9.17.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 23) which recorded 0.00.
For Total Debt / Equity (X), as of Mar 24, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 0.00.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.66. It has decreased from 0.71 (Mar 23) to 0.66, marking a decrease of 0.05.
For Current Ratio (X), as of Mar 24, the value is 0.77. This value is below the healthy minimum of 1.5. It has decreased from 0.91 (Mar 23) to 0.77, marking a decrease of 0.14.
For Quick Ratio (X), as of Mar 24, the value is 0.38. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 23) to 0.38, marking a decrease of 0.21.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 4.81. This value is within the healthy range. It has decreased from 8.67 (Mar 23) to 4.81, marking a decrease of 3.86.
For Interest Coverage Ratio (X), as of Mar 24, the value is 1.17. This value is below the healthy minimum of 3. It has increased from -1.15 (Mar 23) to 1.17, marking an increase of 2.32.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is -5.71. This value is below the healthy minimum of 3. It has decreased from -3.50 (Mar 23) to -5.71, marking a decrease of 2.21.
For Enterprise Value (Cr.), as of Mar 24, the value is 108.58. It has increased from 90.15 (Mar 23) to 108.58, marking an increase of 18.43.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.04. This value is within the healthy range. It has increased from 0.69 (Mar 23) to 1.04, marking an increase of 0.35.
For EV / EBITDA (X), as of Mar 24, the value is 47.93. This value exceeds the healthy maximum of 15. It has increased from -18.82 (Mar 23) to 47.93, marking an increase of 66.75.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.05. This value is within the healthy range. It has increased from 0.71 (Mar 23) to 1.05, marking an increase of 0.34.
For Price / BV (X), as of Mar 24, the value is 1.14. This value is within the healthy range. It has increased from 0.78 (Mar 23) to 1.14, marking an increase of 0.36.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.05. This value is within the healthy range. It has increased from 0.71 (Mar 23) to 1.05, marking an increase of 0.34.
For EarningsYield, as of Mar 24, the value is -0.19. This value is below the healthy minimum of 5. It has increased from -0.41 (Mar 23) to -0.19, marking an increase of 0.22.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation. If you have any questions or need more detailed insights, please feel free to reach out.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Lasa Supergenerics Ltd as of February 25, 2025 is: ₹29.24

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of February 25, 2025, Lasa Supergenerics Ltd is Undervalued by 35.37% compared to the current share price 21.60

Default values used*: Default value of 15 for Stock P/E is used

Intrinsic Value of Lasa Supergenerics Ltd as of February 25, 2025 is: 19.62

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of February 25, 2025, Lasa Supergenerics Ltd is Overvalued by 9.17% compared to the current share price ₹21.60

Default values used*: Default value of 15 for Stock P/E is used

Last 5 Year EPS CAGR: -32.90%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a low average Working Capital Days of 21.67, which is a positive sign. The company has higher reserves (73.40 cr) compared to borrowings (45.90 cr), indicating strong financial stability.	The stock has a low average ROCE of 6.44%, which may not be favorable. The stock has a high average Cash Conversion Cycle of 29.44, which may not be favorable. The company has not shown consistent growth in sales (152.22) and profit (-4.11).

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lasa Supergenerics Ltd:
1. Net Profit Margin: -20.82%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: -8.24% (Industry Average ROCE: 13.99%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: -22.47% (Industry Average ROE: 10.73%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): -5.71
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 0.38
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 0 (Industry average Stock P/E: 46.86)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Lasa Supergenerics Ltd. is a Public Limited Listed company incorporated on 11/11/2016 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24233MH2016PLC274202 and registration number is 274202. Currently Company is involved in the business activities of Manufacture of veterinary preparations. Company's Total Operating Revenue is Rs. 104.34 Cr. and Equity Capital is Rs. 50.10 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Chemicals - Speciality - Others	Plot No C-4, C-4/1, MIDC, Lote Parshuram Industrial Area, Ratnagiri Dist. Maharashtra 415722	investor@lasalabs.com http://www.lasalabs.com

Management
Name	Position Held
Dr. Omkar Pravin Herlekar	Chairman & Managing Director
Mr. Umesh S Pawar	Executive Director
Mr. Ajay Sukhwani	Independent Director
Ms. Manali Bhagtani	Independent Director
Ms. Ekta Gurnasinghani	Independent Director
Mr. Hardesh Tolani	Independent Director

FAQ

What is the latest intrinsic value of Lasa Supergenerics Ltd?

Let's break down Lasa Supergenerics Ltd's intrinsic value simply:

We calculate intrinsic value using the PE Ratio Method - comparing the company's current price-to-earnings ratio with its historical average and industry peers. Think of it like checking if a stock is "on sale" compared to its typical pricing.

As of 25 February 2025:

Calculated Fair Value: ₹29.24
Current Market Price: ₹21.60
Variance: 35.37% higher

This suggests Lasa Supergenerics Ltd is currently undervalued by 35.37%. For context:

Market Cap: 108 Cr.
52-Week Range: 33.5/19.0
Reserves (Sep 2024): 41 Cr
Liabilities: 147 Cr

Remember: The PE method gives a snapshot based on earnings multiples. While useful for quick comparisons, investors should also consider growth prospects, industry trends, and economic conditions. This calculation assumes historical PE ratios remain relevant - always verify with current market dynamics.

What is the Market Cap of Lasa Supergenerics Ltd?

The Market Cap of Lasa Supergenerics Ltd is 108 Cr..

What is the current Stock Price of Lasa Supergenerics Ltd as on 25 February 2025?

The current stock price of Lasa Supergenerics Ltd as on 25 February 2025 is ₹21.6.

What is the High / Low of Lasa Supergenerics Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Lasa Supergenerics Ltd stocks is 33.5/19.0.

What is the Stock P/E of Lasa Supergenerics Ltd?

The Stock P/E of Lasa Supergenerics Ltd is .

What is the Book Value of Lasa Supergenerics Ltd?

The Book Value of Lasa Supergenerics Ltd is 18.1.

What is the Dividend Yield of Lasa Supergenerics Ltd?

The Dividend Yield of Lasa Supergenerics Ltd is 0.00 %.

What is the ROCE of Lasa Supergenerics Ltd?

The ROCE of Lasa Supergenerics Ltd is 6.45 %.

What is the ROE of Lasa Supergenerics Ltd?

The ROE of Lasa Supergenerics Ltd is 13.2 %.

What is the Face Value of Lasa Supergenerics Ltd?

The Face Value of Lasa Supergenerics Ltd is 10.0.